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Introduction
Acute pulmonary inflammation (ALI) is characterized by
migration of polymorphonuclear neutrophils (PMNs)
into the different compartments of the lung, passing an
endothelial and epithelial barrier. Recent studies showed
evidence that phosphodiesterase (PDE)4-inhibitors stabi-
lized endothelial cells [1]. PDE4B and PDE4D play a
pivotal role in inflammation, whereas blocking PDE4D
is suspected to cause gastrointestinal side effects.
Objectives
To investigate the particular role of PDE4 on PMN
migration and lung epithelium.
Methods
ALI was induced by inhalation of LPS in mice. PDE4-
inhibitors roflumilast and rolipram were administered i.
p. or were nebulized after inflammation to investigate
the impact of PDE-inhibitors on pulmonary epithelium
in vivo. Additional, PDE4-inhibitors were tested regard-
ing to migration of human PMNs through pulmonal
epithelial barrier in vitro. Furthermore the influence of
PDE4-inhibitors on PDE4B and PDE4D expression as
well as on cytokines were analyzed.
Results
Both PDE4-inhibitors decreased transendothelial and
transepithelial migration, whereas roflumilast showed a
superior effect compared to rolipram on the epithelium.
Both inhibitors decreased the chemokines TNFa, IL6,
and CXCL2/3. CXCL1, the strong PMN chemoattractant
secreted by the epithelium [2], was significantly more
reduced by roflumilast compared to rolipram. In vitro
assays with human PMNs and human pulmonary epithe-
lium also emphasized the pivotal role of roflumilast on
the epithelium. Expression of PDE4 subtypes B and D
were both increased in the lungs by LPS, and PDE4 inhi-
bitors decreased mainly PDE4B. Administration of the
PDE-inhibitors still had anti-inflammatory properties
after LPS inhalation and the topical administration of
PDE4-inhibitors was also effective in curbing down PMN
migration, both highlighting the clinical potential of these
compounds.
Conclusions
We determined the pivotal role of the PDE4-inhibitor
roflumilast on lung epithelium and emphasized its main
effect on PDE4B in hyperinflammation.
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